HUTCHMED (China) Limited

HUTCHMED (China) Limited is a biopharmaceutical company engaged in the research, development, and commercialization of innovative targeted therapies and immunotherapies. Its focus lies in treating cancer and immunological disorders, serving patients both in Hong Kong and globally. The company's operations are divided into Oncology/Immunology and Other Ventures. Among its key assets is Savolitinib, an inhibitor primarily aimed at non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another significant compound, Fruquintinib, targets a range of solid tumors, including CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and other gastrointestinal malignancies. Its extensive pipeline also includes Surufatinib, an inhibitor used in various neuroendocrine tumors (NETs), such as pancreatic and non-pancreatic forms, as well as in biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and additional solid tumors. Further therapeutic candidates include HMPL-523, a spleen tyrosine kinase inhibitor developed for hematological cancers and specific chronic immune conditions, and HMPL-689, which targets isoform PI3Kd. The company is also advancing Tazemetostat, an EZH2 inhibitor currently indicated for certain epithelioid sarcoma and follicular lymphoma patients. Other investigational compounds in its portfolio encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; and HMPL-653, designed to treat metastatic solid tumors and tenosynovial giant cell tumors. Additionally, it is developing Epitinib (HMPL-813) and Theliatinib (HMPL-309), both representing further inhibitor therapies. HUTCHMED frequently partners with leading pharmaceutical and biotechnology firms, holding collaboration agreements with entities such as AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. Established in 2000, the company rebranded from Hutchison China MediTech Limited to HUTCHMED (China) Limited in May 2021. Its corporate headquarters are situated in Central, Hong Kong.